Menu Search
Equities

Bioceltix SA

XI3:FRA

Bioceltix SA

Actions
  • Price (EUR)12.28
  • Today's Change-0.14 / -1.13%
  • Shares traded2.00
  • 1 Year change-25.35%
  • Beta--
Data delayed at least 15 minutes, as of May 10 2024 08:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bioceltix SA is a Poland-based biopharmaceutical company, which operates in the field of veterinary medicine. The Company deal with the development of candidates for veterinary medicinal products based on the immunomodulatory properties of mesenchymal stem cells used as the active substance of the drug. Entity's products are intended for the treatment of companion animals. The Company carry out research and development works, which enable clinical trials and full registration of medicinal products in the European Medicines Agency, as is the case with medicines and drugs administered to humans.

  • Revenue in PLN (TTM)0.00
  • Net income in PLN-12.73m
  • Incorporated2018
  • Employees--
  • Location
    Bioceltix SAul. Bierutowska 57-59, bud. IIIWROCLAW 51-317PolandPOL
  • Phone+48 718808771
  • Fax+48 717345509
  • Websitehttps://bioceltix.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.